Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 11/20 | 0.45 |
| ▸ | CTSS | P25774 | 5/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL272661 | 1.00 | CA2 (0.53) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL84553 | 1.00 | CA2 (0.53) | CA2CA1CA7CYP2D6CTSK | |
| Hydrochloric Acid SCHEMBL10594711 | 0.98 | CA2 (0.51) | CA2CA1CA7CYP2D6CTSK | |
| Hydrochloric Acid SCHEMBL29197256 | 0.98 | CA2 (0.51) | CA2CA1CA7CYP2D6CTSK | |
| Hydrochloric Acid SCHEMBL29408471 | 0.98 | CA2 (0.51) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL12523040 | 0.85 | CA2 (0.47) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL18196102 | 0.85 | CA2 (0.47) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL86237 | 0.85 | CA1 (0.50) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL86310 | 0.85 | CA1 (0.50) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL1654201 | 0.85 | CA1 (0.50) | CA2CA1CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250765-A1 | Diazepinones as antiviral agents | CHO HIDETSURA | 2005-11-10 | — | — | US | claimed |
| US-20040116410-A1 | Diazepinones as antiviral agents | CHO HIDETSURA (JP) | 2004-06-17 | — | — | US | claimed |
| EP-4225762-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12612416-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-28 | — | — | US | disclosed |
| US-20250361205-A1 | ENZYME-CLEAVABLE METHADONE PRODRUGS AND METHODS OF USE THEREOF | ENSYSCE BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-12421240-B2 | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12384744-B2 | Enzyme-cleavable methadone prodrugs and methods of use thereof | Ensysce Biosciences Inc. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250213571-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250206744-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-06-26 | — | — | US | disclosed |
| EP-4570805-A1 | TRICYCLIC COMPOUNDS AND MEDICAL USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2025-06-18 | — | — | EP | disclosed |
| WO-2002014324-A2 | DIAZEPINONES AS ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
| US-5683989-A | TREATMENT OF CARDIOVASCULAR AND NERVOUS SYSTEM DISORDERS | NOVO NORDISK A/S (DK) | 1997-11-04 | — | — | US | disclosed |
| US-5484774-A | 2, N6 -disubstituted adenosines, tri-O-ester derivatives and their pharmaceutical compositions to treat ischemias | NOVO NORDISK A/S (DK) | 1996-01-16 | — | — | US | disclosed |
| US-5242943-A | Administering as beta adrenoceptor blocking agents | Louis, William J. (AU) | 1993-09-07 | — | — | US | disclosed |
| US-5051445-A | Cardiovascular disorders such as antiarrhythmia or cardiotonic agents, adrenergic blocking agents | Louis, William J. (AU) | 1991-09-24 | — | — | US | disclosed |
| EP-0177515-B1 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Louis, William John (AU) | 1989-05-31 | — | — | EP | disclosed |
| EP-0177515-A4 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | SANDOZ LTD (CH) | 1986-09-23 | — | — | EP | disclosed |
| EP-0177515-A1 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | SANDOZ LTD (CH) | 1986-04-16 | — | — | EP | disclosed |
| WO-1985004403-A1 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANDOZ LTD. (CH) | 1985-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421240-B2 | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease | HRH3, HRH4, HRH2 | CA2 385/4885CA1 243/4885CA7 964/4885 |
| US-20050250765-A1 | Diazepinones as antiviral agents | ZC3HAV1, ECI1, ZC3HAV1L | CA2 3287/4885CA1 2495/4885CA7 1623/4885 |
| US-12612416-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, CLCN2, CLIC1 | CA2 867/4885CA1 4506/4885CA7 3623/4885 |
| US-20250213571-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | CA2 4725/4885CA1 4610/4885CA7 4686/4885 |
| US-12435078-B2 | Pyridazinones and methods of use thereof | PDXK, ATP6V1B1, REN | CA2 3937/4885CA1 4778/4885CA7 3368/4885 |
| US-20250206744-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | CA2 4099/4885CA1 4430/4885CA7 2443/4885 |
| US-12384744-B2 | Enzyme-cleavable methadone prodrugs and methods of use thereof | CES2, ACHE, COMT | CA2 1606/4885CA1 599/4885CA7 974/4885 |
| US-20250361205-A1 | ENZYME-CLEAVABLE METHADONE PRODRUGS AND METHODS OF USE THEREOF | CES2, ACHE, COMT | CA2 1606/4885CA1 599/4885CA7 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.